Esbriet Tablet, Coated
Product Images NDC 83107-029

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esbriet (NDC 83107-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Legacy Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Esbriet 01)

Chemical structure of pirfenidone, the active ingredient in ESBRIET, shown as a molecular diagram illustrating the arrangement of carbon, nitrogen, and oxygen atoms in the compound.*

FDA Label Image

Figure 1 (Esbriet 02)

A cumulative distribution curve comparing absolute change in % predicted forced vital capacity (FVC) from baseline to week 52 for ESBRIET versus placebo. The x-axis shows change in %FVC, ranging from -30% to 10%, and the y-axis shows the percentage of patients, from 0% to 100%. The chart highlights percentages of patients with worsening or no decline in lung function for both groups.*

FDA Label Image

Figure 2 (Esbriet 03)

A line graph depicting the mean change in forced vital capacity (FVC) in milliliters over 52 weeks. The graph compares two groups: one treated with ESBRIET and one with placebo. The ESBRIET group shows a slower decline in FVC compared to the placebo group across the study period.*

FDA Label Image

Figure 3 (Esbriet 04)

A Kaplan-Meier survival curve chart comparing percentage of patients alive over time in weeks between ESBRIET (pirfenidone) and placebo groups. The chart includes patient counts at risk for both groups at multiple time points up to 120 weeks, with hazard ratio (HR) and 95% confidence interval indicated.*

FDA Label Image

Image Description (Esbriet 06a)

Esbriet (pirfenidone) tablets 267 mg coated tablets packaging label. The label shows a 270-tablet count and the labeler is Legacy Pharma USA Inc. Storage instructions and dosage reference are noted, along with the NDC 83107-028-27 barcode.*

FDA Label Image

Image Description (Esbriet 07a)

Esbriet 801 mg coated tablets containing pirfenidone, labeled for oral use. The label includes dosage strength, quantity of 90 tablets, and storage instructions at 25°C (77°F) with permitted excursions. It also displays the NDC code 83107-029-90 and the labeler Legacy Pharma USA Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.